11 research outputs found
Use of the index of pulmonary vascular disease for predicting long-term outcome of pulmonary arterial hypertension associated with congenital heart disease
AimsLimited data exist on risk factors for the long-term outcome of pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD-PAH). We focused on the index of pulmonary vascular disease (IPVD), an assessment system for pulmonary artery pathology specimens. The IPVD classifies pulmonary vascular lesions into four categories based on severity: (1) no intimal thickening, (2) cellular thickening of the intima, (3) fibrous thickening of the intima, and (4) destruction of the tunica media, with the overall grade expressed as an additive mean of these scores. This study aimed to investigate the relationship between IPVD and the long-term outcome of CHD-PAH.MethodsThis retrospective study examined lung pathology images of 764 patients with CHD-PAH aged <20 years whose lung specimens were submitted to the Japanese Research Institute of Pulmonary Vasculature for pulmonary pathological review between 2001 and 2020. Clinical information was collected retrospectively by each attending physician. The primary endpoint was cardiovascular death.ResultsThe 5-year, 10-year, 15-year, and 20-year cardiovascular death-free survival rates for all patients were 92.0%, 90.4%, 87.3%, and 86.1%, respectively. The group with an IPVD of â„2.0 had significantly poorer survival than the group with an IPVD <2.0 (Pâ=â.037). The Cox proportional hazards model adjusted for the presence of congenital anomaly syndromes associated with pulmonary hypertension, and age at lung biopsy showed similar results (hazard ratio 4.46; 95% confidence interval: 1.45â13.73; Pâ=â.009).ConclusionsThe IPVD scoring system is useful for predicting the long-term outcome of CHD-PAH. For patients with an IPVD of â„2.0, treatment strategies, including choosing palliative procedures such as pulmonary artery banding to restrict pulmonary blood flow and postponement of intracardiac repair, should be more carefully considered
Digital therapeutics for essential hypertension using a smartphone application: A randomized, openâlabel, multicenter pilot study
Abstract Hypertension is the most considerable but treatable risk factor for cardiovascular disease. Although physicians prescribe multiple antihypertensive drugs and promote lifestyle modifications, the realâworld blood pressure (BP) control rate remains poor. To improve BP target achievement, we developed a novel digital therapeuticâthe HERB software systemââto manage hypertension. Here, we performed a randomized pilot study to assess the safety and efficacy of the HERB system for hypertension. We recruited 146 patients with essential hypertension from March 2018 to March 2019. We allocated eligible patients to the intervention group (HERB system + standard lifestyle modification) or control group (standard lifestyle modification alone). The primary outcome was the mean change from baseline to 24 weeks in 24âhour systolic BP (SBP) measured by ambulatory blood pressure monitoring (ABPM). The baseline characteristics in each group were well balanced; the mean age was approx. 57 years, and 67% were male. In the primary end point at 24 weeks, HERB intervention did not lower the mean change of 24âhour SBP by ABPM compared with the controls (adjusted difference: â0.66 mmHg; p = .78). In an exploratory analysis focusing on antihypertensive drugânaĂŻve patients aged <65, the effects of the HERB intervention were significantly greater than the control for reducing 24âhour SBP by ABPM at 16 weeks (adjusted difference: â7.6 mmHg; p = .013; and morning home SBP at 24 weeks (adjusted difference â 6.0 mmHg; p = .012). Thus, the HERB intervention did not achieve a primary efficacy end point. However, we observed that antihypertensive drugânaĂŻve adult hypertensive patients aged <65 years could be a potential HERB systemâeffective target for further investigations of the efficacy of the system
Recent Progress in Plasma Control Studies on the Improvement of Plasma Performance in Heliotron J
Recent progress in plasma control studies on the improvement of plasma performance in Heliotron J is reviewed. The supersonic molecular beam injection (SMBI) fueling is successfully applied to Heliotron J plasma. A supersonic H2-beam is effectively injected to increase fueling efficiency and generate a peaked density profile. Local fueling with a short-pulsed SMBI can increase the core plasma density and avoid the degradation arising from edge cooling. Second harmonic electron cyclotron current drive (ECCD) experiments were conducted by launching a focused Gaussian beam with a parallel refractive index of â0.05 †Nâ †0.6. Results show that the electron cyclotron (EC) driven current is determined not only by Nâ but also by local magnetic field (B) structure where the EC power is deposited. Detailed analysis of the observed Nâ and B dependences is in progress with a ray-tracing simulation using the TRAVIS code. Fast ion velocity distribution was investigated using fast protons generated by ion cyclotron resonant frequency (ICRF) minority heating. For the standard configuration in Heliotron J, charge exchange neutral particle analysis (CX-NPA) measurements show higher effective temperature of fast minority protons in the on-axis resonance case compared to that in the HFS (high field side) off-axis resonance case. However, the increase in bulk ion temperature in the HFS resonance case is larger than that in the on-axis resonance